Interestingly, PD-1 inhibition has shown efficacy in a small series of patients with relapsed/refractory primary CNS lymphoma and T-DLBCL patients with CNS relapse [41]. This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.